论文部分内容阅读
目的探讨康复新液联合泮托拉唑治疗消化性溃疡的临床疗效及安全性。方法将2015年3月-2016年3月医院收治的消化性溃疡患者116例作为研究对象,按随机数字表法分为2组,每组各58例。对照组患者给予奥美拉唑联合果胶铋进行治疗,观察组患者给予康复新液联合泮托拉唑治疗,连续服药2周后,根据胃黏膜活检组织学检查结果并结合临床症状改善情况,判断临床疗效;依据治疗期间患者服药后产生头晕、呕吐、腹胀、食欲减退四项不良反应的发生情况评价其安全性。结果观察组治疗总有效率为91.38%,高于对照组的74.14%(P<0.05);观察组不良反应发生率为8.62%,低于对照组的37.93%(P<0.01)。结论对于消化性溃疡患者,采取康复新液联合泮托拉唑治疗具有较好的疗效,同时安全性高,值得在临床推广应用。
Objective To investigate the clinical efficacy and safety of Kangfuxin solution combined with pantoprazole in the treatment of peptic ulcer. Methods One hundred and sixty-six patients with peptic ulcer admitted from March 2015 to March 2016 in our hospital were divided into two groups according to the random number table method, 58 cases in each group. Patients in the control group were treated with omeprazole combined with pectin bismuth. Patients in the observation group received Kangfuxin Solution combined with pantoprazole. After 2 weeks of continuous administration, according to histological findings of gastric mucosa biopsy and improvement of clinical symptoms, To determine the clinical efficacy; based on the treatment of patients with dizziness, vomiting, bloating, loss of appetite after the occurrence of four adverse reactions evaluation of its safety. Results The total effective rate of observation group was 91.38%, which was higher than that of control group (74.14%, P <0.05). Adverse reaction rate in observation group was 8.62%, which was lower than that in control group (37.93%, P <0.01). Conclusions For patients with peptic ulcer, taking rehabilitation of new liquid combined with pantoprazole treatment has good curative effect, and high safety, it is worth in the clinical application.